Urinary neopterin as a prognostic index of survival time in HIV-1 infection

International Journal of STD and AIDS

Volumn 9, Issue 6, 1998, Pages 326-329

  Rogstad, Karen E ^a,b   Morgan, Linda ^c   Hughes, James ^c  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^b ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^c NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

AIDS; CD4; HIV; Neopterin; Surrogate markers; Survival

Indexed keywords

NEOPTERIN;

ADOLESCENT; ADULT; ARTICLE; CHILD; DIAGNOSTIC VALUE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL TIME; URINALYSIS;

CD4 LYMPHOCYTE COUNT; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV-1; HUMANS; LONGITUDINAL STUDIES; MALE; NEOPTERIN; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVORS;

EID: 0031806226     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/0956462981922340     Document Type: Article

References (38)

1. Biggar RJ. AIDS incubation 189/HIV seroconverters from different exposure groups. AIDS 1990;4:1059-66
2. Osmond D, Charlebois E, Lang W, Shiboski S, Moss A. Changes in AIDS survival time in two San Francisco cohorts of homosexual men, 1983 to 1993. JAMA 1994;271:1083-7
3. Phillips AN, Sabin CA, Elford J, Bofill M, Janossy G, Lee CA. Use of CD4 lymphocyte count to predict long term survival free of AIDS after HIV infection. BMJ 1994;1309:309-13
4. Melbye M, Grossman RJ, Goedert JJ, Eyster ME, Biggar RJ. Risk of AIDS after herpes zoster. Lancet 1987;1:728-31
5. Medley GF, Anderson RM, Cox DR, Billard L. Incubation period of AIDS in patients infected via blood transfusion. Nature 1987;328:719-21
6. Auger I, Thomas P, De Gruttola V, et al. Incubation periods for paediatric AIDS patients. Nature 1988;336:575-7
7. Lagakos SW, De Gruttola V. The conditional latency distribution of AIDS for persons infected by blood transfusion. J Acquir Immune Defic Syndr 1989;2:84-7
8. Pollock MS, Safai B, Dupont B. HLA DR5 and DR2 are susceptibility factors for acquired immunodeficiency syndrome with Kaposi's sarcoma in different ethnic subpopulations. Dis Markers 1983;1:135-9
9. Richman DD, Bozette SA. The impact of syncytium inducing phenotype of human immunodeficiency virus on disease progression. J Infect Dis 1994;169:968-74
10. Bossette SA, McCutchan JA, Speetor SA, Wright B, Richman DD. A cross-sectional comparison of persons with syncytium and non-syncytium inducing human immunodeficiency virus. J Infect Dis 1993;168:1374-9
11. Kozal MJ, Shafer RW, Winters MA, et al. A mutation in human immunodeficiency virus reverse transcriptase and decline in CD4 lymphocyte numbers in long term zidovudine recipients. J Infect Dis 1993;167:526-32
12. Mellors JW, Rinaldo Jr CR, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996;272:1167-70
13. Moss AR, Bacchetti P, Osmond D, et al. Seropositivity for HIV and the development of AIDS or AIDS-related conditions: three year follow-up of the San Francisco General Hospital Cohort. BMJ 1988;296:745-50
14. Polk BF, Fox R, Brookmeyer R, et al. Predictors of the acquired immunodeficiency syndrome developing in a cohort of seropositive homosexual men. N Engl J Med 1987;316:61-6
15. Mellors JW, Rinaldo C, Gupta P, et al. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996;272:1167-70
16. Fahey JL, Taylor JMG, Detels R, et al. The prognostic value of cellular and serological markers in infection with human immunodeficiency virus type I. N Engl J Med 1990;322: 166-72
17. Lange JMA, de Wolf F, Goudsmit J. Markers for progression in HIV infection. AIDS 1989;3(suppl 3):S153-S160
18. Lacey JN, Forbes MA, Waugh MA, Cooper EH, Hambling MH. Serum B-2 microglobulin and human immunodeficiency virus infection. AIDS 1987;1:123-7
19. Fuchs D, Hausen A, Reibnegger G, Werner ER, Dierich MP, Wachter H. Neopterin as a marker for activated cell-mediated immunity: application in HIV infection. Immunol Today 1988;9:150-5
20. Ziegler I, Rokos H. Pteridines and the immune response. J Immunol Immunopharm 1986;6:169-77
21. Melmed RN, Taylor JM, Detels R, Bozorgmehni M, Fahey JL. Serum neopterin changes in HIV infected subjects: indicator of significant pathology, CD4 T cell change, and the development of AIDS. J Aquir Immune Defic Syndr 1989; 2:70-6
22. Kramer A, Wiktor SZ, Fuchs D, et al. Neopterin: a predictive marker of acquired immune deficiency syndrome in human immunodeficiency virus infection. J Acquir Immune Defic Syndr 1989;2:291-8
23. Fuchs D, Keibnegger G, Wachter H, Jaeger H, Popescu M, Kaboth W. Neopterin levels correlating with Walter Reed Staging Classification in human immunodeficiency virus (HIV) infection. Ann Intern Med 1987;107:784-5
24. Hausen A, Fuchs D, Konig K, Wachter H. Determination of neopterin in human urine by reversed phase high performance liquid chromatography. J Chromatography 1982;227:61-70
25. Altman DG. Practical Statistics for Medical Research. London: Chapman and Hall, 1991
26. Huber C, Batchelor JR, Fuchs D, et al. Immune response associated production of neopterin. Release from macrophages primarily under control of interferon gamma. J Exp Med 1984;160:310
27. Werner E, Bichler A, Daxenbichler G, et al. Determination of neopterin in serum and urine. Clin Chem 1987;33:62-6
28. Wachter H, Fuchs D, Hausen A, Reibnegger G, Werner E. Neopterin as a marker for activation of cellular immunity: immunological basis and clinical application. Adv Clin Chem 1989;27:81-141
29. Fuchs D, Jaeger H, Popescu M, et al. Comparison of serum and urine neopterin concentrations in patients with HIV-1 infection. Clin Chim Acta 1990;187:125-30
30. Fuchs D, Milstien S, Kramer A, et al. Urinary neopterin concentrations vs total neopterins for clinical utility. Clin Chem 1989;35(12):2305-7
31. Hofmann B. Neopterin and human immunodeficiency virus infection. Eur J Clin Chem Clin Biochem 1993;31(4):191-5
32. Fuchs D, Banekouich M, Hausen A, et al. Neopterin estimation compared with the ratio of T-cell sub-populations in persons infected with human immunodeficiency virus-1. Clin Chem 1988;34(12):2415-17
33. Fuchs D, Kramer A, Reibnegger G, et al. Neopterin and beta 2-microglobulin as prognostic indices in human immunodeficiency virus type-1 infection. Infection 1991;19(suppl 2): S98-102
34. Fuchs D, Spira TJ, Hausen A, et al. Neopterin as a predictive marker for disease progression in human immunodeficiency virus type 1 infection. Clin Chem 1989;35(8):1746-9
35. Hutterer J, Fuchs D, Eder G, et al. Neopterin as discriminating and prognostic parameter in healthy homosexuals, ARC and AIDS patients. Wien Klin Wochenschr 1987;99(15):531-5
36. Kaboth W, Tilz GP, Wachter H. Immune activation markers to predict AIDS and survival in HIV-1 seropositives. Immunol Lett 1990;26(1):75-9
37. Zangerle R, Fuchs D, Reibnegger G, Fritsch P, Wachter H. Markers for disease progression in intravenous drug users infected with HIV-1. AIDS 1991;5(8):985-91
38. O'Brien WA, Hartigan PM, Martin D, et al. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. N Engl J Med 1996;334:426-31